TY - JOUR
T1 - Resolution of racemic carbovir and selective inhibition of human immunodeficiency virus by the (-) enantiomer
AU - Vince, Robert
AU - Brownell, Jay
N1 - Funding Information:
work was supported Cancer Institute. by Steve G. Carter
PY - 1990/5/16
Y1 - 1990/5/16
N2 - (+/-) Carbocyclic 2′,3′-didehydro-2′,3′-dideoxyguanosine (Carbovir; NSC 614846) is an antiretroviral agent which is undergoing preclinical evaluation for the treatment of AIDS. Racemic carbovir was separated into its D and L enantiomers by the action of adenosine deaminase on the 2,6-diaminopurine precursor. Subsequent evaluation of the enantiomers against human immunodeficiency virus type 1 revealed that the antiviral activity of carbovir resides in the (-) isomer that is analagous to the nucleoside, β-D-2′,3′-didehydro-2′,3′-dideoxyguanosine.
AB - (+/-) Carbocyclic 2′,3′-didehydro-2′,3′-dideoxyguanosine (Carbovir; NSC 614846) is an antiretroviral agent which is undergoing preclinical evaluation for the treatment of AIDS. Racemic carbovir was separated into its D and L enantiomers by the action of adenosine deaminase on the 2,6-diaminopurine precursor. Subsequent evaluation of the enantiomers against human immunodeficiency virus type 1 revealed that the antiviral activity of carbovir resides in the (-) isomer that is analagous to the nucleoside, β-D-2′,3′-didehydro-2′,3′-dideoxyguanosine.
UR - http://www.scopus.com/inward/record.url?scp=0025322824&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0025322824&partnerID=8YFLogxK
U2 - 10.1016/0006-291X(90)91115-9
DO - 10.1016/0006-291X(90)91115-9
M3 - Article
C2 - 2346492
AN - SCOPUS:0025322824
SN - 0006-291X
VL - 168
SP - 912
EP - 916
JO - Biochemical and Biophysical Research Communications
JF - Biochemical and Biophysical Research Communications
IS - 3
ER -
